Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. - Wikidata - wikimedia - TriplyDB

Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.

Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.

http://www.wikidata.org/entity/Q35775292

about

Diagnosis and management of the primary headache disorders in the emergency department setting Acute migraine: Current treatment and emerging therapies Headache management: pharmacological approaches Orofacial pain management: current perspectives.Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.Migraine pathogenesis and state of pharmacological treatment options Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal Headache-type adverse effects of NO donors: vasodilation and beyond Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis.The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects Almotriptan and zolmitriptan in the acute treatment of migraine.CGRP receptor antagonists: an expanding drug class for acute migraine?Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache.Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis.Migraine and risk of stroke in older adults: Northern Manhattan Study.Eletriptan in migraine.Migraine treatment throughout the lifecycle.Migraine, cerebrovascular disease and the metabolic syndrome Can we develop neurally acting drugs for the treatment of migraine?Rizatriptan in migraine.Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan.The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study.Optimizing migraine therapy: evidence-based and patient-centered care.Sumatriptan: update and review.Migraine: emerging treatment options for preventive and acute attack therapy.Tailoring management strategies for the patient with menstrual migraine: focus on prevention and treatment.Treatment-emergent CNS symptoms following triptan therapy are part of the attack.Understanding the causes and prevention of menstrual migraine: the role of estrogen.Current migraine management - patient acceptability and future approaches.Migraine and cardiovascular disease: possible mechanisms of interaction Triptans Use for Migraine Headache among Nonelderly Adults with Cardiovascular Risk Triptans and troponin: a case report Sumatriptan/naproxen sodium combination for the treatment of migraine.The pharmacological management of migraine, part 1: overview and abortive therapy.Randomized, controlled trial of telcagepant for the acute treatment of migraine.Migraine in the triptan era: progresses achieved, lessons learned and future developments.Calcitonin gene-related peptide receptor antagonists for migraine.Headache and cardiovascular disease: old symptoms, new proposals.

P2860

Q24651176-2A8141FB-5CE0-4873-BFCE-B7AF644F28A1 Q24654649-FF7C4171-9B3C-4E37-9578-D28B2575E155 Q27316751-43B381A1-FC88-46D1-9BFD-6A7EFE60DFE7 Q30442178-5176D180-A702-4B84-AF6E-4B00EB2C829F Q30660036-32A6C6C8-524C-45F3-B0C5-670367143CEC Q30886663-17F3CE69-BCFA-4FF0-BE49-EB3972014A92 Q30968082-76CE0F7C-4253-46DA-B4FD-AAEE86E0BE40 Q33755782-BDA34015-95C9-4BD1-8027-DD8C5702CDFA Q33812736-19A2945F-30E8-44AD-8007-9C18808D2CB7 Q34094599-B71E8881-DB9B-43E1-8712-BD0705A0FBFF Q34462428-0DE12AAD-B57F-482D-B3A2-BC2B2C44CBF4 Q34573136-E6DCF295-B9E5-4C46-BB94-2CFA7808D8A5 Q34637610-B2062C75-FDCB-4976-B308-70BCC3F03916 Q35684215-F7F824C3-EA6B-4C77-97DA-A769B1AD7D4C Q35884646-C6D9DD4B-2F21-4C33-85FD-C83768DB4B51 Q36005662-0BE80893-2FAE-4D88-8854-11BC451A4A39 Q36106757-78DD32F1-5105-4CAB-988B-AB634389F120 Q36153372-EC0F48AD-AA49-4204-981C-D335EB35E200 Q36239499-65AE9934-547E-4B8D-B0B7-FCEA5AB65009 Q36240187-3275A09A-1FF1-4044-B2C1-7DE76F7C97D5 Q36257191-9D77EB17-D6EB-48AE-8C96-43AD5626CD8F Q36260631-E83FAEF8-3AC0-4DA8-B6AC-73AF3FAA0603 Q36340711-5432366E-20E2-49F2-A8DA-3BF889E58EEE Q36342969-B7568B25-6B2C-4A8E-B195-45B6204651A2 Q36511332-A105694A-F0F3-46CC-99D8-7E6319DE900C Q36543148-5DEC6D6F-BDDA-42E0-8FEA-C1AE3988118E Q36580576-FABF29A5-52A5-421E-AB9E-198B10817017 Q36625038-40FBA7C9-6975-4E1A-88E7-CEE68F152B30 Q36768331-BB88B2D6-EC93-433A-A0E5-364C38D815B4 Q36938684-7942FA17-90A9-4D5F-AF18-566050136280 Q37106936-7D4C56E9-61DC-42C5-93E2-6007A5A3BD3C Q37213760-87693068-F9E8-45A1-83AA-FC39A66B4452 Q37218677-D36457DA-9720-4384-B3F5-E3CAA028D13A Q37251602-76C43A79-88EA-4E44-8B4C-DEA2F44E8BBE Q37256688-AC560D32-A1E2-427C-BAB4-14FAC859575E Q37340160-9C86902C-67AB-4336-9185-9201BDAB80E1 Q37368387-E605F207-1AE7-4F37-8054-CA0E2CFA5C5A Q37558323-F9F891ED-1611-4768-85ED-4B675D4322F5 Q37756158-804B221A-B6E5-4CDC-B190-48A5291AB3B7 Q37798812-0EE9D09F-4860-46A0-BA14-6242BE93E2C2

P2860

Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.

http://www.wikidata.org/entity/Q35775292

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Consensus statement: cardiovas ...... e acute treatment of migraine.

@ast

Consensus statement: cardiovas ...... e acute treatment of migraine.

@en

type

label

Consensus statement: cardiovas ...... e acute treatment of migraine.

@ast

Consensus statement: cardiovas ...... e acute treatment of migraine.

@en

prefLabel

Consensus statement: cardiovas ...... e acute treatment of migraine.

@ast

Consensus statement: cardiovas ...... e acute treatment of migraine.

@en

P1433

Q35775292-1E49F38E-33FF-4E05-BB08-E09551D44DD5

P1476

Q35775292-7C22CC5E-7D12-4A4A-9415-1B7AAD735865

P2093

Q35775292-1224F9F9-CB1A-4519-BABE-3CB20854CD17

Q35775292-37B64B38-AC2B-4C06-8D4E-DF3005D695C9

Q35775292-3A1A2C22-C5A4-4647-88C4-7811DBBC1312

Q35775292-44BF7584-F013-4AAA-9057-A2D1BABE0947

Q35775292-5A46D526-4BA7-4177-B016-3F3986A4EAEE

Q35775292-6FDD542B-7B7F-4381-9798-A49731214B0A

Q35775292-73A1F4CC-9042-4BA6-A708-E90B5B9A5B17

Q35775292-8997CF16-00BE-4E67-A7B7-0E3D264DFF64

Q35775292-89FEE65D-9931-4079-AF0A-7A0F5870558E

Q35775292-8BAF9677-57ED-4CE9-89F5-D66C52CAC764

P2860

Q35775292-004D9A3F-8CF7-4DC0-9C4A-BD1FCAC3B936

Q35775292-0A239770-44CE-4CB0-9FDB-94589FCA212B

Q35775292-0E5A4DBB-E1CF-4F0E-A290-098A62E297B3

Q35775292-10991A49-9FFF-4002-9A97-78D24FF7F494

Q35775292-1212E143-A6FE-47DA-850D-FCFBBE53F4A5

Q35775292-13074B9D-B285-438B-9931-85E571B28FC4

Q35775292-131B42AA-FF0A-4BA1-8D94-06414039D9F7

Q35775292-14E841BE-DA3E-4F9E-991A-65BC5376EF36

Q35775292-1D1BECD5-9973-45DF-8C2C-185AB8401CAE

Q35775292-1DC237ED-7533-4417-86C7-901BAFE0916E

P304

Q35775292-713CAC68-FCA8-4C84-9EFA-FEF726D0B162

P31

Q35775292-61009D90-9ADB-4B59-9ABE-2B83EC2AFE5F

P356

Q35775292-7FDEFD54-C608-4C1F-B949-D99D03DC9E26

P433

Q35775292-7BEA36B6-0AFC-4ADC-9ACF-2BCD9511B91D

P478

Q35775292-3A89151E-ADBC-4B0F-94E1-75E7BDD7CCC5

P50

Q35775292-405F0016-0EBC-4206-B337-E1257C963E28

Q35775292-5F84AAB4-0F51-495F-90C9-C9B45413C096

Q35775292-B3141E26-A9A7-4525-BE37-0BCFED35E571

Q35775292-F4F2EE02-85BA-458A-B2DE-C8498ECAA941

P577

Q35775292-1D640CC9-61DB-4474-935E-DEAB6588EEC4

P5875

Q35775292-A291C025-3725-4206-93C1-BF31178B5885

P698

Q35775292-8CC644D5-A7CC-4EAF-9FFF-B9A90088CC2A

P921

Q35775292-69B5CCFF-F8DD-4EE8-B2A6-65956F3A381A

Q35775292-EFAC5748-FFA9-48DB-9173-E6F6D08DCE4E

P356

J.1526-4610.2004.04078.X

P1433

P1476

Consensus statement: cardiovas ...... e acute treatment of migraine.

@en

P2093

Antoinette MaassenVanDenBrink

http://www.w3.org/2001/XMLSchema#string

David Matchar

http://www.w3.org/2001/XMLSchema#string

Hassan Loutfi

http://www.w3.org/2001/XMLSchema#string

Jane Saiers

http://www.w3.org/2001/XMLSchema#string

K Michael Welch

http://www.w3.org/2001/XMLSchema#string

R Allan Purdy

http://www.w3.org/2001/XMLSchema#string

Steven Hahn

http://www.w3.org/2001/XMLSchema#string

Susan Hutchinson

http://www.w3.org/2001/XMLSchema#string

Timothy R Smith

http://www.w3.org/2001/XMLSchema#string

Triptan Cardiovascular Safety Expert Panel

http://www.w3.org/2001/XMLSchema#string

P2860

The global burden of disease study: implications for neurology

Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Tolerability and efficacy of almotriptan in the long-term treatment of migraine.

The relationship of migraine and stroke.

Migraine and stroke in young women.

Migraine--current understanding and treatment.

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.

5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519

Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks.

P304

414-425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1526-4610.2004.04078.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Peter J. Goadsby

Richard B. Lipton

Stephen D. Silberstein

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8559423

http://www.w3.org/2001/XMLSchema#string

P698

15147249

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

migraine disorder